4
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- EGFR+
- Tumour stage
- Metastatic
- Control Arm
- Platinum-based chemotherapy doublet
- Treatment Setting
- 1st line stage III or IV non-squamous, with EGFR mutation
- Trial Name
- EURTAC
Primary Outcome(s)
- Primary Outcome(s)
- PFS (crossover allowed)
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 5.2 months
- PFS Gain
- 4.5 months
- PFS HR
- 0.37 (0.25-0.54)
- OS Control
- 19.35 months
- OS HR
- NS
- Toxicity Comment
- 15% less severe adverse reactions
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Toxicity adjustment
- 1+
- Final non-curative Score
- 4
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate